Xpovio (selinexor) / Menarini, NeoPharm, Karyopharm, Jiangsu Hansoh Pharma, Antengene, FORUS Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

78 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xpovio (selinexor) / Karyopharm
ACTRN12621001361897p: A single arm, open-label study of Exportin 1 inhibitor selinexor in relapsed/refractory central nervous system (CNS) Lymphoma and in relapsed/refractory CNS Myeloma

Not yet recruiting
2
20
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Central nervous system diffuse large B cell lymphoma; Central nervous system myeloma
 
 
ACTRN12621001361897: A single arm, open-label study of Exportin 1 inhibitor selinexor in relapsed/refractory central nervous system (CNS) Lymphoma and in relapsed/refractory CNS Myeloma

Not yet recruiting
2
20
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Central nervous system diffuse large B cell lymphoma, Central nervous system myeloma
 
 
ACTRN12622001366741: Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial

Recruiting
2
120
 
Australasian Myeloma Research Consortium, Australasian Myeloma Research Consortium
Multiple Myeloma
 
 
ACTRN12622001313729: ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd)

Recruiting
2
140
 
Australasian Leukaemia & Lymphoma Group, Australasian Leukaemia & Lymphoma Group
Relapsed/ Refractory Multiple Myeloma
 
 
2014-002444-40: A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma. Inductie en consolidatie behandeling met selinexor gecombineerd met bortezomib en dexamethason voor patiënten met Multipel Myeloom met verslechtering van het ziektebeeld.

Ongoing
2
37
Europe
bortezomib, selinexor (20 mg), selinexor (10mg), KPT-330, Velcade, Velcade
Erasmus MC, karyopharm
A Phase II study of Selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory Multiple Myeloma. Inductie en consolidatie behandeling met selinexor gecombineerd met bortezomib en dexamethason voor patiënten met Multipel Myeloom met verslechtering van het ziektebeeld.
 
 
2014-001876-75: Study for patients with leukemic cells in their bone marrow

Ongoing
2
230
Europe
selinexor (20 mg), KPT-330, Tablet
HOVON Foundation, HOVON Foundation, Karyopharm Therapeutics
patients ≥ 66 years with: - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML, or - acute leukemia's of ambiguous lineage according to WHO 2008 or - a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R > 4.5, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04]
 
 
2017-001736-19: Selinexor, cyclophosphamide and prednisolone compared to cyclophosphamide and prednisolone in patients with multiple myeloma

Not yet recruiting
2
60
Europe
Selinexor, Cyclophosphamide, Prednisolone, Tablet, Cyclophosphamide, Prednisone
University of Leeds
Multiple myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2017-002326-21: Clinical Trial with selinexor (KPT-330), bortezomib and low-dose dexamethasone plus daratumumab (SELIBORDARA) for the treatment of patients with refractory or relapsed and refractory multiple myeloma Ensayo clínico de selinexor (KPT-330), bortezomib y dosis baja de dexametasona más daratumumab (SELIBORDARA) para el tratamiento de pacientes con mieloma múltiple en recaída y/o refractario

Ongoing
2
62
Europe
DARZALEX, VELCADE, Selinexor, Infusion, Solution for injection, Tablet, DARZALEX, VELCADE
Fundación PETHEMA, Fundación Pethema
Patients with refractory or relapsed and refractory multiple myeloma Pacientes con mieloma múltiple en recaída y/o refractario, patients with multiple myeloma Pacientes con mieloma múltiple, Diseases [C] - Cancer [C04]
 
 
MUKtwelve, NCT06212596: Selinexor, Cyclophosphamide and Prednisone in Myeloma

Completed
2
66
Europe
Selinexor, Cyclophosphamide, Prednisone
University of Leeds
Relapsed or Refractory Multiple Myeloma
10/22
11/23
2020-006060-89: Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe)

Not yet recruiting
2
50
Europe
Selinexor, Revlimid, Bortezomib, Dexamethasone, Tablet, Capsule, hard, Injection, Selinexor, Revlimid, Bortezomib, Dexamethasone
Odense University Hospital, Nordic Myeloma Study Group
Multiple myeloma, Multiple Myeloma, Diseases [C] - Cancer [C04]
 
 
2021-006229-23: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. Studio pilota di fase II di Selinexor in combinazione con Ifosfamide, Etoposide e Desametasone (SIDE) in pazienti con linfoma a cellule T periferiche recidivato o refrattario.

Not yet recruiting
2
30
Europe
HOLOXAN, Selinexor, Decadron, Etoposide, [HOLOXAN], [Selinexor], [Decadron], [Etoposide], Powder for solution for injection/infusion, Tablet, Solution for injection, Concentrate for solution for injection/infusion, HOLOXAN - 1 G POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, DECADRON - 8 MG/2 ML SOLUZIONE INIETTABILE 3 FIALE DA 2 ML, ETOPOSIDE TEVA - 1 FLACONE 5 ML 20MG/ML
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, Diseases [C] - Cancer [C04]
 
 
GEM-SELIBORDARA, NCT03589222: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Recruiting
2
62
Europe
Selinexor, Daratumumab, Bortezomib, Dexamethasone
PETHEMA Foundation
Refractory Multiple Myeloma
08/23
08/23
SPODUMENE, NCT05478993: Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

Recruiting
2
21
RoW
SPD：Selinexor Oral Tablet, Pomalidomide, Dexamethasone
Peking University People's Hospital, Qingdao Municipal Hospital
Multiple Myeloma
07/24
07/25
NCT04768881: Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Active, not recruiting
2
40
US
Selinexor, KPT-330, XPOVIO®, Pembrolizumab, KEYTRUDA®
Karyopharm Therapeutics Inc
Locally Advanced Unresectable or Metastatic Melanoma
09/23
01/24
SEARCH, NCT03992339: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
60
RoW
ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle, Selinexor
Antengene Corporation
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
12/23
06/24
NCT02436707: Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Recruiting
2
320
Canada
Ibrutinib, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Mesna, Cyclophosphamide, Etoposide, G-CSF, Selinexor
Canadian Cancer Trials Group, Janssen, LP, Roche Pharma AG, Karyopharm Therapeutics Inc
Lymphoma
12/25
12/26
NCT05974085: XPO-1 in Combination With RCHOP for DH/TH Lymphoma

Recruiting
2
10
RoW
Selinexor+RCHOP
Zhejiang Cancer Hospital
Double Hit Lymphoma, Triple Hit Lymphoma
12/23
03/24
NCT04661137: A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Recruiting
2
96
US
Selinexor 60 MG, KPT-330, Selinexor 80 MG, Selinexor 100 MG, Carfilzomib, Kyprolis, Pomalidomide, Pomalyst, Daratumumab, Darzalex, Dexamethasone, Dextenza, Ozurdex, Neofordex, others
Hackensack Meridian Health, Karyopharm Therapeutics Inc
Multiple Myeloma
01/25
01/25
PORCH, NCT04998760: A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( )

Not yet recruiting
2
96
RoW
ATG-008, ATG-010
Qi Zhou
1. Relapsed Ovarian Cancer 2. Metastatic Ovarian Cancer 3. Endometrial Cancer 4. Cervical Cancer
01/24
04/24
NCT05322330: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
2
20
RoW
Selinexor, XPO-1 Inhibitor, Flu, Fludarabine, CTX, Cyclophosphamide, CAR-T, Chimeric antigen receptor-modified T (CAR-T) cell therapy
The First Affiliated Hospital of Soochow University, West China Hospital, The General Hospital of Western Theater Command PLA, The Affiliated People's Hospital of Ningbo University Ningbo Yinzhou People's Hospital Community, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Yixing People's Hospital, Affiliated Hospital of Jiangnan University, Wuxi Second People's Hospital
Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
02/24
02/24
ESSENTIAL, NCT03627403: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Checkmark Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Nov 2022 - Nov 2022: Data of reduced spleen volume from ESSENTIAL trial for myelofibrosis
Checkmark New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Nov 2021 - Nov 2021: New interim data from ESSENTIAL trial in previously treated myelofibrosis at ASH 2021
Checkmark Data from ESSENTIAL trial for myelofibrosis
More
Active, not recruiting
2
17
US
Selinexor
University of Utah, Karyopharm Therapeutics Inc
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis
08/23
03/25
NCT06062641: Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Not yet recruiting
2
50
RoW
SR-GDP
Ruijin Hospital
Relapsed or Refractory B-cell Lymphoma
04/24
09/27
NCT02835222: Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

Checkmark Data from trial for older patients with acute myeloid leukemia at ASH 2020
Dec 2020 - Dec 2020: Data from trial for older patients with acute myeloid leukemia at ASH 2020
Recruiting
2
100
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Daunorubicin Hydrochloride, Cerubidin, Cerubidine, Cloridrato de Daunorubicina, Daunoblastin, Daunoblastina, Daunoblastine, Daunomycin Hydrochloride, Daunomycin, hydrochloride, Daunorubicin.HCl, Daunorubicini Hydrochloridum, FI-6339, Ondena, RP-13057, Rubidomycin Hydrochloride, Rubilem, Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Untreated Adult Acute Myeloid Leukemia
06/25
06/25
SABLe, NCT04717700: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting
2
50
Europe
Selinexor 20 MG Oral Tablet, Xpovio, Bortezomib Injection, Velcade, Lenalidomide capsule, Revlimid, Dexamethasone Oral, Neofordex
Ida Bruun Kristensen, Karyopharm Therapeutics Inc, Odense Patient Data Explorative Network
Multiple Myeloma
06/24
06/29
XPORT-MM-028, NCT04414475 / 2020-000821-22: A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM

Recruiting
2
141
Europe, RoW
Selinexor, KPT-330, XPOVIO, Dexamethasone, Decadron, Bortezomib, Velcade, Pomalidomide, Imnovid
Karyopharm Therapeutics Inc
Multiple Myeloma, Refractory
06/24
06/25
NCT05900882: SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Recruiting
2
35
RoW
Selinexor, S, Bortezomib, V, Lenalidomide, R, Dexamethasone, d
The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
08/24
06/25
NCT05951855: Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Recruiting
2
42
RoW
Selinexor, X, Chidamide, C
The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (Relapsed/Refractory)
09/24
03/25
NCT04756401: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Recruiting
2
52
US
Carfilzomib, Kyprolis, PR-171, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Quality-of-Life Assessment, Quality of Life Assessment, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
09/24
12/27
ChiCTR2200064695: A phase II trial of selinexor, pomadomide, bortezomib combined with dexamethasone in newly diagnosed multiple myeloma with renal insufficiency

Not yet recruiting
2
62
 
Selinexor, pomadomide, bortezomib combined with dexamethasone
Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Clinical Research Incubation Project in 2022
Multiple myeloma
 
 
ChiCTR2200057942: Clinical study of selinexor combined with CHOP regimen with or without ASCT followed by selinexor monotherapy maintenance therapy in patients with newly diagnosed peripheral T-cell lymphoma

Not yet recruiting
2
32
 
selinexor + CHOP
Jiangsu Province Hospital; Jiangsu Provincial People's Hospital, Antengene Corporation
PTCL
 
 
NCT04925193: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Recruiting
2
25
US
Selinexor, Pomalidomide, Daratumumab, Carfilzomib, Dexamethasone
University of Colorado, Denver, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Multiple Myeloma in Relapse
11/24
11/25
NCT06169215: Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Recruiting
2
70
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Daratumumab, Daratumumab Biosimilar HLX15, Daratumumab-fihj, Darzalex, HLX15, HuMax-CD38, JNJ-54767414, Daratumumab and Hyaluronidase-fihj, DARA Co-formulated with rHuPH20, DARA/rHuPH20, Daratumumab + rHuPH20, Daratumumab and Hyaluronidase, Daratumumab with rHuPH20, Daratumumab-rHuPH20, Daratumumab/Hyaluronidase-fihj, Daratumumab/rHuPH20 Co-formulation, Darzalex Faspro, Darzalex/rHuPH20, HuMax-CD38-rHuPH20, Recombinant Human Hyaluronidase Mixed with Daratumumab, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Multiple Myeloma
09/26
09/26
LAUNCH, NCT04877275: ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Recruiting
2
50
RoW
Selinexor (80mg/d), ATG-010, Selinexor (100mg/d), Pegylated liposomal doxorubicin, PLD, Dexamethasone, Dex, Cyclophosphamide, CTX
Chunyan Sun, MD
Multiple Myeloma
12/24
12/24
NCT05597345: Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Recruiting
2
15
US
Selinexor
University of Rochester, Karyopharm Therapeutics Inc
Smoldering Multiple Myeloma
12/24
12/24
NCT04562870 / 2020-003809-60: A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Hourglass Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis
Checkmark First patient dosed as a monotherapy in patients with 2L myelofibrosis
Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis
Active, not recruiting
2
112
Europe, US, RoW
Selinexor, Physician's Choice Treatment
Karyopharm Therapeutics Inc
Myelofibrosis
01/25
01/25
AVS, NCT05736978: Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

Recruiting
2
58
RoW
Azacitidine, Venetoclax, ABT-199, Selinexor, XPO1 inhibitor
Shanghai Tong Ren Hospital
AML, MRD
03/25
03/27
SAV, NCT05736965: A Study of Selinexor in Combination With Azacitidine and Venetoclax ( Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

Recruiting
2
58
RoW
Selinexor, xpo1 inhibitor, Azacitidine, Venetoclax, ABT199
Shanghai Tong Ren Hospital
AML, Adult
03/25
04/27
NCT05850286: A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Recruiting
2
20
RoW
anti-BCMA CAR-T, VRD-based Regimen
Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma
04/25
04/27
NCT05870917: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Recruiting
2
20
RoW
anti-BCMA CAR-T, Bortezomib, Lenalidomide and Dexamethasone
Institute of Hematology & Blood Diseases Hospital, China
Plasma Cell Leukemia
04/25
04/27
NCT05333458: Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study

Recruiting
2
77
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Advanced Alveolar Soft Part Sarcoma, Advanced Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
05/25
05/25
NCT05969158: Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma

Not yet recruiting
2
90
NA
Hetrombopag, SHR8735
Sun Yat-sen University
Chemotherapy-Induced Thrombocytopenia
05/25
08/25
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Hourglass Jan 2023 - Dec 2023 : Market entry for endometrial cancer
Recruiting
2
50
RoW
Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product
Li Zhiming, Antengene Corporation
DLBCL Germinal Center B-Cell Type
07/25
12/25
NCT04941937: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Recruiting
2
90
RoW
Selinexor, ATG-010/KPT-330, Thalidomide, fǎn yìng tíng, Lenalidomide, Revlimid, An xian, Pomalidomide, POMALYST, Dexamethasone, Dex
Juan Du
Multiple Myeloma
12/25
12/25
NCT05833893: Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

Recruiting
2
10
RoW
XPO1 inhibitor, COPL
Chinese PLA General Hospital
nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma
12/25
12/26
SELVEDge, NCT05530421: Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Recruiting
2
33
US
Selinexor, Xpovio, Venetoclax, Venclexta, Venclyxto, Dexamethasone, Decadron, Ozurdex, Dexycu
University of Miami, Karyopharm Therapeutics Inc
Relapsed and Refractory Multiple Myeloma
03/26
03/28
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Recruiting
2
118
US
Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA
Karyopharm Therapeutics Inc
Myelofibrosis, Moderate Thrombocytopenia
04/26
10/28
NCT04782687: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Recruiting
2
100
US
Selinexor, Xpovio, Dexamethasone Oral, Daratumumab, Darzalex, Lenalidomide, Revlimid
US Oncology Research, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
05/26
05/26
SeliSarc, NCT06114004: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma

Recruiting
2
88
Europe
Selinexor 20 MG, KPT-330, Gemcitabine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Sarcoma,Soft Tissue
05/26
05/26
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Recruiting
2
35
US
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
Checkmark Data from SADAL trial in DLBCL
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT05985161: A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Recruiting
2
36
US
Selinexor
Memorial Sloan Kettering Cancer Center
Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST, Nephroblastoma, XPO1 Gene Mutation, Solid Tumor
08/29
08/29
NCT05983276: Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Recruiting
2
40
US
Decitabine, Dacogen, Carboplatin, Paraplatin, Paclitaxel, Abraxane, Selinexor, Xpovio, Nexpovio
Loyola University, Karyopharm Therapeutics Inc
Ovarian Cancer
08/30
08/31
2017-004761-28: A study of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal tumors (GISTs) Estudio de Selinexor en combinación con imatinib en pacientes con tumores gastrointestinales (GISTs) metastasicos o irresecables

Not yet recruiting
1/2
41
Europe
Selinexor, Glivec, KTP-330, STI571, Coated tablet, Tablet, Glivec
Grupo Español de Investigación en Sarcomas, Karyopharm
Gastrointestinal stromal tumor (GIST) Tumor del estroma gastrointestinal, Gastrointestinal stromal tumor (GIST) is a rare cancer affecting the digestive tract or nearby structures within the abdomen. Tumor del estroma gastrointestinal es un cancer raro que afecta el tracto digestivo y otras estructuras adyacentes en el abdomen, Diseases [C] - Cancer [C04]
 
 
MyDRUG, NCT03732703: Myeloma-Developing Regimens Using Genomics

Checkmark Data from MyDRUG study for MM at ASH 2022
Dec 2022 - Dec 2022: Data from MyDRUG study for MM at ASH 2022
Recruiting
1/2
228
US
Abemaciclib, dexamethasone, ixazomib, pomalidomide, abemaciclib: Verzenio, LY2835219, ixazomib: Ninlaro, MLN2238, pomalidomide: Pomalyst, Enasidenib, dexamethasone, ixazomib, pomalidomide, enasidenib: AG221, IDHIFA, Cobimetinib, dexamethasone, ixazomib, pomalidomide, cobimetinib: Cotellic, GDC-0973, RG7420, Erdafitinib, dexamethasone, ixazomib, pomalidomide, erdafitinib: G-024, JNJ-42756493, JNJ-493, Venetoclax, dexamethasone, ixazomib, pomalidomide, venetoclax: Venclexta: ABT-199, Daratumumab, dexamethasone, ixazomib, pomalidomide, daratumumab: Darzalex, Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide, Belantamab mafodotin: BLENREP, GSK2857916, Selinexor, dexamethasone, ixazomib, pomalidomide, Selinexor: XPOVIO
Multiple Myeloma Research Consortium, AbbVie, Celgene Corporation, Eli Lilly and Company, Genentech, Inc., Janssen, LP, Takeda, GlaxoSmithKline, Karyopharm Therapeutics Inc
Relapsed Refractory Multiple Myeloma
02/22
02/24
NCT03095612: Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Terminated
1/2
41
US
Selinexor, KPT-330, Docetaxel
University of Texas Southwestern Medical Center, Karyopharm Therapeutics Inc
Non-small Cell Lung Cancer
11/22
03/23
SeliGIST, NCT04138381: Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

Active, not recruiting
1/2
30
Europe
Selinexor, Drug Combination, Single agent, Imatinib
Grupo Espanol de Investigacion en Sarcomas
Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma, Drug Toxicity, Drug Use
04/23
04/23
NCT06449482: Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

Recruiting
1/2
20
RoW
Selinexor, XPO1-i, Venetoclax, BCL-2i, Azacitidine
Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia, Adult
04/25
04/25
XPORT-GBM-029, NCT04421378: A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Terminated
1/2
74
Canada, US
Selinexor, KPT-330, XPOVIO, Temozolomide (TMZ), Temodar, Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Karyopharm Therapeutics Inc
Glioblastoma Multiforme
07/23
07/23
NCT05975944: Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Recruiting
1/2
49
RoW
Selinexor，Olaparib
Tianjin Medical University Cancer Institute and Hospital
Extensive-stage Small Cell Lung Cancer
09/23
05/24
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
SPRINT, NCT04256707 / 2021-000617-16: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Recruiting
1/2
120
RoW
Selinexor 100 mg, Xpovio®, Docetaxel, Taxotere®, Pembrolizumab, Keytruda®, FOLFIRI, Selinexor 40 mg, Selinexor 80 mg, Selinexor 60 mg
Karyopharm Therapeutics Inc
Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors
03/25
03/25
NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Recruiting
1/2
139
US
Surgical resection, Proton beam radiation therapy, Pazopanib, VOTRIENT®, Ifosfamide, Ifex, Doxorubicin, Adriamycin®, Rubex®, Selinexor, XPOVIO®
St. Jude Children's Research Hospital
Non-rhabdomyosarcoma, Adipocytic Neoplasm, Liposarcoma
06/34
06/37
NCT05577364: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Recruiting
1/2
54
RoW
Selinexor, exportin 1 (XPO1) inhibitor, R-CHOP Protocol, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Sun Yat-sen University, Fudan University, Antengene Corporation
EBV-Positive Diffuse Large B-Cell Lymphoma, Nos
12/24
02/26
NCT04856189: Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Recruiting
1/2
12
US
Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
Mamta Parikh, Karyopharm Therapeutics Inc, National Cancer Institute (NCI)
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Urothelial Carcinoma
05/24
05/24
NCT05035745: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recruiting
1/2
63
RoW
Talazoparib, Selinexor
National University Hospital, Singapore
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
11/24
11/25
NCT03147885: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Recruiting
1/2
69
US
Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
12/25
12/26
THEORY, NCT05675813: Genotype-guided Treatment in Newly Diagnosed PTCL

Recruiting
1/2
264
RoW
CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab, standard CHOP
Ruijin Hospital, The First Affiliated Hospital of Nanchang University, Peking University Third Hospital, Wuhan TongJi Hospital, West China Hospital, Nanfang Hospital, Southern Medical University, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of Soochow University, The Second Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, Beijing Tongren Hospital, Peking University People's Hospital, Sun Yat-sen University, The First Affiliated Hospital of Anhui Medical University, The First Hospital of Jilin University
Peripheral T Cell Lymphoma
07/26
07/28
NCT04891744: Selinexor in Combination With Thalidomide and Dexamethasone in RRMM

Not yet recruiting
1/2
48
RoW
Selinexor, ATG-010, Thalidomide, fǎn yìng tíng, Dexamethasone, Dex
Li Zheng
Multiple Myeloma
12/24
12/24
STOMP, NCT02343042: Selinexor and Backbone Treatments of Multiple Myeloma Patients

Checkmark From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Jun 2021 - Jun 2021: From STOMP trial in combination with Pomalyst & low dose dexamethasone for r/r multiple myeloma
Checkmark Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Dec 2020 - Dec 2020: Data from STOMP trial in combination with pomalidomide and dexamethasone for early line multiple myeloma at ASH 2020
Checkmark Data from STOMP trial in combination with carfilzomib and dexamethasone for multiple myeloma at ASH 2020
More
Active, not recruiting
1/2
300
Canada, US
Selinexor, KPT-330, XPOVIO®, Dexamethasone, Decadron®, Lenalidomide, Revlimid®, Pomalidomide, Pomalyst®, Bortezomib, Velcade®, Daratumumab, Darzalex®, Carfilzomib, Kyprolis®, Ixazomib, Ninlaro®, Elotuzumab, Empliciti®, Clarithromycin, Biaxin, Belantamab Mafodotin, BLENREP, Mezigdomide, BMS-986348, CC-92480
Karyopharm Therapeutics Inc, Bristol-Myers Squibb
Multiple Myeloma
04/27
04/27
NCT04764942: Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Recruiting
1/2
81
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Pomalidomide, 4-Aminothalidomide, Actimid, CC-4047, Imnovid, Pomalyst, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Static X-Ray, X-Ray, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, CT, CT Scan, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, Proton magnetic resonance spectroscopic imaging, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blood Sample Collection
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
03/25
03/26
SWATCH, NCT05265975: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Recruiting
1/2
84
RoW
ATG-010, Selinexor, Lenalidomide, Rituximab
Antengene Corporation
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
03/25
06/25
NCT05432804: Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Suspended
1/2
97
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
06/26
06/26
NCT05422027: Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Recruiting
1/2
42
RoW
Selinexor, ATG-010, Xpovio, Bortezomib, Velcade, Lenalidomide, Revlimid, Dexamethasone, Dexamethasone Acetate
Xia Zhongjun, Antengene Corporation
Multiple Myeloma
06/25
12/25
NCT05498636: SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Not yet recruiting
1/2
67
RoW
Selinexor combined with Prednisone, Etoposide, and Lenalidomide
The Affiliated Hospital of Qingdao University
DLBCL
07/25
12/25
ChiCTR2200065167: The validity and safety of Selinexor combined with Azacitidine for the treatment of de novo myelodysplastic syndromes with excessive blasts (MDS-EB1 or EB2): A prospective, single-arm, Phase Ib/II clinical study

Not yet recruiting
1/2
32
 
Selinexor combined with azacytidine
The First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital of Zhejiang University, None
Myelodysplastic syndromes
 
 
XVRD in the treatment of high risk-NDMM, ChiCTR2200062602: Selinexor (ATG-010) plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma

Not yet recruiting
1/2
42
 
Selinexor, Bortezomib, Lenalidomide, Dexamethasone
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, self-raised
Multiple Myeloma
 
 
NCT05698147: Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Recruiting
1/2
30
RoW
Selinexor, ATG-010, Rituximab, RiTUXimab Injection, Methotrexate, MTX
Tong Chen, MD, Antengene Corporation
Central Nervous System Lymphoma
06/26
12/26
NCT05099003: A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Recruiting
1/2
210
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Nexpovio, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Glioblastoma, Not Otherwise Specified, Malignant Glioma
06/27
06/27

Download Options